{"groups":[{"description":"All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.\n\nTotal Body Irradiation (TBI): Total body irradiation given in 8 fractions over 4 days (total dose of 12 Gy).\n\nDonor Lymphocyte Infusion (DLI): After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.\n\nCyclophosphamide: Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days\n\nMycophenolate Mofetil (MMF): Started the day before the transplant to prevent graft versus host disease (GVHD)\n\nTacrolimus: Started the day before the transplant to prevent graft-versus-host disease (GVHD)\n\nHematopoietic stem cell transplantation (HSCT): One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-do","id":"FG000","title":"TJU 2 Step Regimen"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}